SCHEMBL2970540

SCHEMBL2970540

CCCC(=O)Nc1ccc(Sc2ccc(C)cc2Nc2ccnc3nc(C)ccc23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
SMN1; SMN2 Q16637 5/20 0.43
HPGD P15428 4/20 0.43
PKM P14618 1/20 0.43
ALDH1A1 P00352 3/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
HSD17B10 Q99714 2/20 0.41
TP53 P04637 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
MAPT P10636 3/20 0.41
JAK2 O60674 1/20 0.41
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2970598 0.91 SMN1; SMN2 (0.43) KDM4ESMN1; SMN2HPGDPKMALDH1A1
SCHEMBL2023477 0.89 AURKA (0.41) KDM4ESMN1; SMN2HPGDPKMALDH1A1
SCHEMBL2961608 0.89 RAB9A (0.46) KDM4ESMN1; SMN2HPGDPKMALDH1A1
SCHEMBL2968955 0.88 MAPT (0.45) KDM4ESMN1; SMN2HPGDPKMALDH1A1
SCHEMBL2968604 0.87 SMN1; SMN2 (0.38) KDM4ESMN1; SMN2HPGDPKMALDH1A1
SCHEMBL2970821 0.86 MET (0.37) KDM4ESMN1; SMN2HPGDPKMALDH1A1
SCHEMBL2970840 0.86 SMN1; SMN2 (0.37) KDM4ESMN1; SMN2HPGDPKMALDH1A1
SCHEMBL2964541 0.85 CETP (0.47) KDM4ESMN1; SMN2HPGDALDH1A1NPC1
SCHEMBL2968986 0.84 PIM1 (0.41) KDM4EHPGDALDH1A1HSD17B10TP53
SCHEMBL2961153 0.84 SREBF2 (0.44) KDM4ESMN1; SMN2HPGDPKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 KDM4E 1822/4885SMN1; SMN2 3135/4885HPGD 3704/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 KDM4E 1822/4885SMN1; SMN2 3135/4885HPGD 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.